Dyslipidemia Management 2026

NeuroWiki

2026 ACC/AHA Dyslipidemia Guideline Summary

This is a condensed summary of the 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia for Atherosclerotic Cardiovascular Disease Risk Reduction (Blumenthal et al., Circulation 2026;153:e00–e00). This replaces the 2018 Guideline on the Management of Blood Cholesterol. Recommendations are listed by Class of Recommendation (COR) and Level of Evidence (LOE).

🔹 Bottom Line: Key Changes from 2018 Guideline

PREVENT-ASCVD replaces PCE (Pooled Cohort Equations): New risk equations estimate both 10-year and 30-year ASCVD (atherosclerotic cardiovascular disease) risk, include kidney function (eGFR) and HbA1c, and remove race as a variable
30-year risk added: For adults with low 10-year risk but high 30-year risk (≥10%), initiating LLT (lipid-lowering therapy) is reasonable to reduce cumulative atherogenic exposure
LDL-C + non-HDL-C dual targets: All treatment thresholds now specify both LDL-C (low-density lipoprotein cholesterol) and non-HDL-C goals
ApoB (apolipoprotein B) endorsed as optional target: Can be used for residual risk assessment, especially in hypertriglyceridemia
Ezetimibe before PCSK9i (PCSK9 inhibitor): Ezetimibe no longer requires failing before adding PCSK9 mAb (monoclonal antibody) — can be added simultaneously or sequentially based on degree of LDL-C lowering needed
Bempedoic acid elevated: Now has ASCVD outcomes data (CLEAR Outcomes) — COR (Class of Recommendation) 2a for secondary prevention, primary prevention in statin-intolerant
Inclisiran included: Approved for LDL-C lowering; CVOT (cardiovascular outcomes trial) data pending — considered second-line PCSK9 inhibitor (COR 2a)
CAC (coronary artery calcium)-guided treatment expanded: Detailed tiered recommendations by CAC score (1–99, 100–299, 300–999, ≥1000) with specific LDL-C goals
HeFH (heterozygous familial hypercholesterolemia) management refined: FH-specific risk scores now available; standard PREVENT-ASCVD should NOT be used for FH
Lp(a) (lipoprotein(a)) recommendations formalized: Elevated Lp(a) ≥50 mg/dL (≥125 nmol/L) warrants early aggressive risk factor management

🧠 Bottom Line for Neurologists

Ischemic stroke & TIA are qualifying ASCVD events — all post-stroke patients merit high-intensity statin therapy
Most stroke patients qualify as "very high risk" → LDL-C target <55 mg/dL: Ischemic stroke counts as a major ASCVD event. "Very high risk" = ≥2 major events OR 1 major event + ≥2 high-risk conditions (HTN, diabetes, age >65, CAD, HF, current smoking, LDL-C >100 on max therapy). Since most stroke patients have at least 2 of these comorbidities, the majority will meet very high risk criteria and need LDL-C <55, non-HDL-C <85
ICAD (intracranial atherosclerotic disease): Recurrent stroke despite medical therapy → very high risk → LDL-C target <55 mg/dL. TST trial showed LDL-C <70 reduced recurrent stroke by 22% vs <100
Large artery atherosclerosis stroke: Aggressive lipid management with high-intensity statin ± ezetimibe ± PCSK9 mAb. FOURIER showed 16% stroke reduction; ODYSSEY showed 27% stroke reduction
Carotid stenosis post-CEA/CAS: Secondary prevention targets apply — LDL-C <70 (or <55 if very high risk)
Drug interactions: Avoid simvastatin/lovastatin with CYP3A4-inhibiting drugs. Enzyme-inducing AEDs (carbamazepine, phenytoin) reduce statin efficacy → use rosuvastatin or pravastatin. Cyclosporine (MG, transplant) → lowest statin dose
Anti-HMGCR necrotizing myopathy: Rare but important — persistent proximal weakness + elevated CK after statin discontinuation → check anti-HMGCR antibodies → requires immunosuppression

1. Screening & Lipid Measurement

Who to Screen

Universal lipid screening in children and adolescents at age 9–11 years and again at 17–21 years (COR 1, LOE B-NR)
In adults ≥20 years, measure fasting or nonfasting lipid panel as part of global CVD risk assessment (COR 1, LOE B-NR)
Earlier screening at ages 2+ if family history of premature CVD or FH

What to Measure

Marker	Key Points	When Preferred
LDL-C	Primary target for LLT. Fasting vs nonfasting differ minimally (~8 mg/dL). If TG >400, direct LDL-C or use Martin-Hopkins equation	All patients
Non-HDL-C	= TC − HDL-C. Captures all atherogenic lipoproteins (LDL + VLDL + IDL + Lp(a)). Does NOT require fasting	When TG elevated; secondary target alongside LDL-C
ApoB	Direct count of atherogenic particles. Better predictor when LDL-C discordant with non-HDL-C. Goal: <55–90 mg/dL based on risk	Hypertriglyceridemia, metabolic syndrome, diabetes, residual risk assessment
Lp(a)	Genetically determined, mostly stable over life. ≥50 mg/dL (≥125 nmol/L) = elevated. Screen once. Assays NOT standardized — report in nmol/L preferred	Once in all adults; family history of premature CVD; recurrent events despite optimal LLT
Triglycerides	Fasting TG ≥150 mg/dL = persistent hypertriglyceridemia. ≥500 mg/dL = pancreatitis risk. Non-fasting TG ≥175 mg/dL triggers fasting confirmation	All patients; fasting if elevated nonfasting

Monitoring Lipids on Therapy

Repeat lipid panel 4–12 weeks after initiating or adjusting LLT (COR 1, LOE A)
Then repeat every 3–12 months as needed to assess adherence and LDL-C attainment
Routine hepatic transaminase or CK monitoring is NOT recommended in asymptomatic patients on statins (COR 3: No Benefit)

2. Risk Assessment

PREVENT-ASCVD Equations (Replaces PCE)

Use for adults 30–79 years without established ASCVD (COR 1, LOE B-NR)
Estimates 10-year and 30-year risk of ASCVD (MI, stroke, fatal CHD)
New variables: eGFR, HbA1c (or diabetes status), zip code–level Social Deprivation Index
Race removed — focuses on modifiable risk factors and social determinants
Risk categories: <3% borderline → 3–<5% borderline → 5–<10% intermediate → ≥10% high
30-year risk ≥10% in low 10-year risk patients may justify LLT initiation
Calculator: prevent.heart.org

PREVENT-ASCVD Risk Calculator

Estimates 10-year and 30-year ASCVD risk — replaces PCE. For adults 30–79 years without established ASCVD.

Age (30–79)

Sex

Total Cholesterol (mg/dL)

HDL Cholesterol (mg/dL)

Systolic BP (mmHg)

eGFR (mL/min/1.73m²)

HbA1c (%)

BMI (kg/m²)

On BP medication Diabetes Current smoker On statin

Simplified estimate using published PREVENT coefficients (Khan SS et al., Circulation 2024). For official calculator with SDI zip code adjustment, use prevent.heart.org

Risk Enhancers

Family history of premature ASCVD (men <55 y, women <65 y)
Persistently elevated LDL-C ≥160 mg/dL
Metabolic syndrome
Chronic kidney disease (eGFR 15–59)
Chronic inflammatory conditions (RA, SLE, psoriasis, HIV)
South Asian ancestry
Premature menopause (<40 y) or preeclampsia history
Elevated Lp(a) ≥50 mg/dL (≥125 nmol/L)
Elevated apoB ≥130 mg/dL
Elevated hsCRP ≥2 mg/L
Ankle-brachial index <0.9

Coronary Artery Calcium (CAC) Scoring

Use for shared decision-making in borderline or intermediate risk (3–<10%) when treatment decision is uncertain (COR 2a, LOE B-NR)
CAC = 0: Withhold statins unless FH, diabetes, or heavy smoking (COR 2b)
CAC 1–99: Moderate-intensity statin reasonable
CAC ≥100: Statin therapy with LDL-C–lowering is recommended (COR 1)
CAC ≥300 or ≥75th percentile: Treat like intermediate-high risk; LDL-C goal <70 mg/dL (COR 1, LOE B-R)
CAC ≥1000: Treat like established ASCVD; LDL-C goal <55 mg/dL (COR 1, LOE B-NR)
CAC is NOT indicated in patients with FH — they should be treated regardless

3. Lifestyle Management

Diet: Emphasize vegetables, fruits, legumes, nuts, whole grains, fish (Mediterranean/DASH pattern). Limit saturated fat <5–6% of calories. Avoid trans fats. (COR 1, LOE A)
Physical activity: ≥150 min/week moderate-intensity or ≥75 min/week vigorous aerobic exercise (COR 1, LOE A)
Weight management: 5–10% weight loss lowers TG by 20–30% and modestly reduces LDL-C
Alcohol: Reduce or eliminate — particularly for hypertriglyceridemia
Supplements: Fish oil, plant stanols/sterols, and psyllium fiber may modestly lower lipids but do NOT substitute for pharmacotherapy in high-risk patients
Referral to dietitian: Reasonable for refractory hypertriglyceridemia or complex lipid phenotypes (COR 2a)

4. Pharmacological Therapy

Statin Intensity

Intensity	Expected LDL-C Reduction	Agents
High	≥50%	Atorvastatin 40–80 mg, Rosuvastatin 20–40 mg
Moderate	30–49%	Atorvastatin 10–20 mg, Rosuvastatin 5–10 mg, Simvastatin 20–40 mg, Pravastatin 40–80 mg, Lovastatin 40–80 mg, Fluvastatin XL 80 mg, Pitavastatin 1–4 mg
Low	<30%	Simvastatin 10 mg, Pravastatin 10–20 mg, Lovastatin 20 mg, Fluvastatin 20–40 mg

Non-Statin LDL-C–Lowering Agents

Agent	Mechanism	LDL-C Reduction	Key Points
Ezetimibe	Cholesterol absorption inhibitor	~18–25%	Well tolerated, generic, first-line add-on. IMPROVE-IT showed MACE reduction in ACS (NNT 50 over 6 y)
PCSK9 mAb (evolocumab, alirocumab)	PCSK9 inhibition → ↑ LDL receptor recycling	~50–60%	FOURIER & ODYSSEY: 1.5% ARR in MACE over ~2.5 y. Subcutaneous injection q2w or monthly. Cost-effective at $5,850/y
Bempedoic acid	ACL inhibitor (upstream of HMG-CoA reductase)	~18–20%	CLEAR Outcomes: 13% RRR in MACE. Does NOT cause myalgia (prodrug activated in liver, not muscle). Elevates BUN, creatinine, uric acid
Inclisiran	siRNA targeting PCSK9 mRNA	~50%	Subcutaneous injection every 6 months. CVOT pending (ORION 4, VICTORION-2). Second-line PCSK9i. Administered by clinician
Bile acid sequestrants	Bile acid binding → ↑ hepatic LDL-R expression	~15–30%	Contraindicated if TG >500. GI side effects limit use. Colesevelam safest in pregnancy. Drug interactions

Triglyceride-Lowering Agents

Agent	Mechanism	TG Reduction	Key Points
Icosapent ethyl (IPE)	Purified EPA	~19%	REDUCE-IT: 25% RRR in MACE. For ASCVD or diabetes with TG 150–499 on statin. Increased bleeding and AF. Mineral oil placebo concern
Fibrates (fenofibrate)	PPARα agonist	30–50%	Lower TG; do NOT reduce ASCVD events as add-on to statin. For pancreatitis prevention with TG ≥500. Avoid gemfibrozil with statins (↑ myopathy). Fenofibrate preferred
Omega-3 fatty acids (prescription)	↓ VLDL synthesis	20–50%	DHA-containing formulations can raise LDL-C. EPA-only (IPE) preferred for ASCVD reduction
Olezarsen	ApoC-III antisense oligonucleotide	~44%	FDA-approved for FCS only. Phase 3 showed significant TG reduction
Niacin	↓ VLDL synthesis	20–30%	NOT recommended — poor tolerability, no ASCVD benefit when added to statin (AIM-HIGH, HPS2-THRIVE)

5. Primary Prevention

Adults 30–79 Years, LDL-C 70–189 mg/dL

First step for ALL: Lifestyle optimization at every risk level (COR 1, LOE A)
LDL-C <70 and non-HDL-C <100: No clear net benefit to initiate LLT

10-Year Risk	Recommendation	Goal
<3% (Borderline)	Healthy behavior counseling. Consider LLT if 30-year risk ≥10% or multiple risk enhancers	LDL-C <100 mg/dL, non-HDL-C <130
3–<5% (Borderline)	Benefit-risk discussion. Moderate-intensity statin reasonable if risk enhancers present	LDL-C <100, non-HDL-C <130
5–<10% (Intermediate)	Moderate-intensity statin for ≥30% LDL-C reduction (COR 1, LOE A). High-intensity reasonable if risk enhancers	LDL-C <100 → <70 if high-intensity; non-HDL-C <100
≥10% (High)	High-intensity statin for ≥50% LDL-C reduction (COR 1, LOE A)	LDL-C <70, non-HDL-C <100

LDL-C ≥160 mg/dL

Regardless of calculated risk, lifestyle counseling is essential
Benefit from earlier LLT initiation based on both 10-year and 30-year risk
Screen for secondary causes: hypothyroidism, nephrotic syndrome, obstructive liver disease, drugs (thiazides, glucocorticoids, atypical antipsychotics, cyclosporine)

6. Secondary ASCVD Prevention

Clinical ASCVD includes: history of MI, ACS, stable angina, coronary revascularization, stroke, TIA, PAD (symptomatic), or aortic aneurysm of atherosclerotic origin.

"Very High Risk" Definition

≥2 major ASCVD events (ACS within 12 mo, MI, ischemic stroke, symptomatic PAD), OR
1 major ASCVD event + ≥2 high-risk conditions (age >65, CABG/PCI, current smoker, diabetes, HF, HTN, LDL-C >100 despite max tolerated statin + ezetimibe)

Treatment Recommendations

Patient Group	Statin	Add-on	LDL-C Goal	Non-HDL-C Goal
ASCVD — Not very high risk	High-intensity (COR 1, LOE A)	Ezetimibe, PCSK9 mAb, or bempedoic acid if not at goal (COR 2a)	<70 mg/dL	<100 mg/dL
ASCVD — Very high risk	High-intensity (COR 1, LOE A)	Ezetimibe AND/OR PCSK9 mAb (COR 1, LOE A); bempedoic acid (COR 2a)	<55 mg/dL	<85 mg/dL
Statin intolerance + ASCVD	Reduced-dose or alternate statin	Bempedoic acid, ezetimibe, PCSK9 mAb, inclisiran	Same as above	Same as above

Optional apoB goal <55 mg/dL for very high risk; <70 mg/dL for high risk
Evidence indicates long-term safety and efficacy of LDL-C to a median of 30 mg/dL over 8 years — no signal for de-escalation

7. Severe Hypercholesterolemia (LDL-C ≥190 mg/dL)

Familial Hypercholesterolemia (FH)

Prevalence of HeFH: ~1:250. Significantly underdiagnosed
2- to 4-fold lifetime ASCVD risk vs general population; adults <35 y up to 17-fold
Do NOT use PREVENT-ASCVD or PCE for FH patients — they underestimate risk
FH-specific risk scores available: Montreal-FH-SCORE, SAFEHEART, FH-Risk Score
CAC = 0 does NOT justify deferring statins in FH
Genetic testing for LDLR, APOB, PCSK9 recommended in possible/probable/definite FH (COR 1, LOE B-NR)
Cascade screening of first-degree relatives (COR 1)

Dutch Lipid Clinic Network (DLCN) Score — FH Diagnosis

Clinical diagnostic criteria for Familial Hypercholesterolemia. Select all that apply:

Family History

First-degree relative with premature CVD (men <55y, women <60y) OR LDL-C >95th percentile (1 pt) First-degree relative with tendon xanthomata and/or arcus cornealis <45y, OR children <18y with LDL-C >95th percentile (2 pts)

Clinical History

Patient has premature coronary artery disease (men <55y, women <60y) (2 pts) Patient has premature cerebral or peripheral vascular disease (men <55y, women <60y) (1 pt)

Physical Examination

Tendon xanthomata (6 pts) Arcus cornealis before age 45 (4 pts)

LDL-C Level (untreated, highest score only)

LDL-C <155 mg/dL (0 pts) LDL-C 155–189 mg/dL (1 pt) LDL-C 190–249 mg/dL (3 pts) LDL-C 250–329 mg/dL (5 pts) LDL-C ≥330 mg/dL (8 pts)

Genetic Testing

Functional mutation in LDLR, APOB, or PCSK9 gene (8 pts)

Treatment by Scenario

Scenario	Treatment	LDL-C Goal
LDL-C ≥190, no FH, no ASCVD, no risk factors	Max tolerated statin + ezetimibe/PCSK9 mAb/bempedoic acid	<100 mg/dL
LDL-C ≥190, HeFH or risk factors, no ASCVD	Max statin + ezetimibe + PCSK9 mAb and/or bempedoic acid	<70 mg/dL
LDL-C ≥190 + clinical ASCVD	Max statin + ezetimibe + PCSK9 mAb + bempedoic acid	<55 mg/dL
HoFH	All above + evinacumab (COR 2b) ± lomitapide (COR 2b) ± lipoprotein apheresis	<100 mg/dL

Lipoprotein Apheresis Indications

HoFH homozygotes with LDL-C >500 mg/dL
HeFH heterozygotes with LDL-C ≥300 mg/dL
HeFH with documented CAD + LDL-C ≥70 mg/dL
HeFH with Lp(a) ≥60 mg/dL + documented CAD/PAD

8. Diabetes Without ASCVD

Age Group	Recommendation	Goal
40–75 y	Moderate-intensity statin (COR 1, LOE A). If multiple risk factors → high-intensity for ≥50% reduction (COR 2a)	LDL-C <100, non-HDL-C <130 → <70 and <100 if high risk
>75 y	Benefit-risk discussion; moderate-intensity statin reasonable (COR 2b)	Same goals if treated
20–39 y	Moderate-intensity statin reasonable if long-standing diabetes (≥10 y T2DM or ≥20 y T1DM) with risk enhancers (COR 2b)	LDL-C <100

Diabetes-Specific Risk Enhancers

Long duration (≥10 y T2DM or ≥20 y T1DM)
Albuminuria ≥30 μg albumin/mg creatinine
eGFR <60 mL/min/1.73 m²
Retinopathy, neuropathy
ABI <0.9

If diabetes + ASCVD + TG 150–499 + LDL-C <100 on max statin: icosapent ethyl may be considered (COR 2b)
Statin therapy slightly increases new-onset diabetes risk (HbA1c increases ~0.06–0.08%) — NOT a reason to discontinue (COR 1, LOE A)

9. Subclinical Atherosclerosis (CAC-Guided Therapy)

CAC Score	Treatment	LDL-C Goal
0	May defer LLT (unless FH, diabetes, heavy smoking)	—
1–99 AU (<75th %ile)	Moderate-intensity statin (COR 2a)	<100 mg/dL
100–299 AU or ≥75th %ile	Statin + LDL-C–lowering; ≥50% reduction (COR 1)	<70 mg/dL
300–999 AU	Intensify therapy; add ezetimibe, PCSK9 mAb, or bempedoic acid (COR 2a)	<55 mg/dL (optional)
≥1000 AU	Treat like established ASCVD (COR 1)	<55 mg/dL
Incidental CAC on nongated CT	Moderate-to-severe: initiate high-intensity statin (COR 2a). Mild: ≥30% LDL-C reduction (COR 2a)	<70 mg/dL

10. Hypertriglyceridemia

Classification

Normal: TG <150 mg/dL (fasting) or <175 mg/dL (nonfasting)
Moderate: 150–499 mg/dL — ASCVD risk
Severe: ≥500 mg/dL — pancreatitis risk
Very severe: ≥1000 mg/dL — consider FCS screening

Secondary Causes to Rule Out

Diseases: Uncontrolled diabetes, hypothyroidism, nephrotic syndrome, CKD, liver disease, Cushing syndrome, SLE
Drugs: Glucocorticoids, estrogens, atypical antipsychotics (olanzapine, clozapine), thiazides, beta-blockers, cyclosporine, tacrolimus, isotretinoin, protease inhibitors, tamoxifen, bile acid sequestrants
Diet/Lifestyle: Alcohol, high-sugar/high-glycemic diet, sedentary lifestyle, obesity

Treatment Algorithm

Step 1: Address secondary causes, optimize diet (reduce alcohol, sugars, refined carbs), exercise, weight loss 5–10%
Step 2: Maximize statin and LDL-C–lowering therapy (statins lower TG 20–40%)
Step 3 (ASCVD + TG 150–499): Consider IPE 4 g/day if LDL-C <100 and non-HDL-C <130 on max statin (COR 2b based on REDUCE-IT)
Step 3 (No ASCVD, TG 150–499): Estimate 10-year risk with PREVENT-ASCVD → optimize statin/LDL-C targets → consider fibrate or omega-3 for persistent TG ≥500
TG ≥500: Fibrate or prescription omega-3 to reduce pancreatitis risk (COR 2a). For FCS: olezarsen (COR 1)
TG ≥1000 (FCS): Very-low-fat diet (<10–15% of calories from fat) + fibrate/omega-3 + olezarsen + lipid specialist referral
When hypertriglyceridemia present and LDL-C/non-HDL-C discordant: apoB preferred over LDL-C for clinical decision-making (COR 2a)

11. Elevated Lp(a)

Elevated Lp(a) ≥50 mg/dL (≥125 nmol/L) affects ~20% of the population
Risk is multiplicative with other risk factors (not merely additive)
An Lp(a) of ~80–100 mg/dL (~200–250 nmol/L) doubles ASCVD risk; 180 mg/dL (~430 nmol/L) increases risk ~4-fold (equivalent to HeFH risk)
Statins do NOT lower Lp(a) — may modestly increase it. This is NOT a reason to discontinue
PCSK9 mAb + lipoprotein apheresis lower Lp(a) as well as LDL-C
Specific Lp(a)-lowering therapies (mRNA therapies, oral small-molecule inhibitors) are in clinical trials

Management Recommendations

In ALL individuals with elevated Lp(a): optimal early control of modifiable CV risk factors (COR 1, LOE B-NR)
If ASCVD + elevated Lp(a) + not at LDL-C/non-HDL-C goal on max statin: add PCSK9 mAb (COR 1, LOE B-R) — addresses both LDL-C and Lp(a)
Post hoc FOURIER and ODYSSEY analyses suggest additional benefit in patients with Lp(a) ≥50 mg/dL
Lipoprotein apheresis is FDA-approved for Lp(a) ≥60 mg/dL (or 130 nmol/L) with FH and CAD/PAD

12. Statin-Attributed Muscle Symptoms (SAMS)

Key Principles

Most commonly reported reason for statin non-adherence (~10% in real-world data)
In RCTs, muscle symptom rates are similar between statin and placebo — "drucebo effect" is common
True statin-related myalgia: bilateral, symmetrical, proximal, onset weeks after initiation, resolves with discontinuation, recurs on rechallenge
Rhabdomyolysis is very rare (~1:100,000)
Statin-induced immune-mediated necrotizing myopathy (anti-HMGCR antibodies) is very rare; requires statin cessation + immunotherapy
CoQ10 supplementation is NOT recommended (COR 3: No Benefit, LOE B-R)
Routine CK monitoring is NOT useful in asymptomatic patients (COR 3: No Benefit)

Risk Factors for SAMS

Age ≥65, low body mass, female sex
Hypothyroidism, CKD, chronic liver disease, diabetes
Alcohol consumption, vigorous exercise
High-dose statin therapy
Drug-drug interactions (especially CYP3A4 inhibitors with lovastatin/simvastatin)
Diseases associated with myalgia (fibromyalgia, polymyalgia rheumatica, primary myopathies)
Gene variants affecting statin metabolism (e.g., SLC01B1)

Management Algorithm

Step 1: Evaluate for secondary causes (DDI, hypothyroidism, exercise). If severe weakness or CK ≥10× ULN: withhold statin, pursue neurologic evaluation
Step 2: Benefit-risk discussion — reinforce ASCVD risk of discontinuation
Step 3: Try alternate statin, lower dose, or every-other-day dosing (long-acting statin: rosuvastatin or atorvastatin)
Step 4: If truly intolerant to ≥2 statins at lowest dose:
- Bempedoic acid (no muscle side effects — hepatic prodrug) ± ezetimibe (COR 1)
- PCSK9 mAb (COR 1 for ASCVD; fewer musculoskeletal side effects than statins)
- Inclisiran (COR 2a — for those unable to tolerate/obtain PCSK9 mAb)
If borderline risk and uncertain about nonstatin therapy: CAC scoring can aid decision (CAC = 0 → may reasonably defer)

13. Drug Interactions

Statin Metabolism & Key Interactions

Statin	Primary CYP Pathway	DDI Risk
Lovastatin, Simvastatin	CYP3A4	Highest — avoid with strong CYP3A4 inhibitors
Atorvastatin	CYP3A4 (lesser extent)	Moderate — dose adjustments with CYP3A4 inhibitors
Fluvastatin	CYP2C9	Low
Pitavastatin	CYP2C9 (minimal)	Low
Rosuvastatin	CYP2C9 (minimal)	Low
Pravastatin	Not CYP-metabolized	Lowest

Cardiovascular Drug Interactions (Table 27)

Interacting Drug	Affected Statin	Recommendation
Amiodarone	Lovastatin, Simvastatin	Limit lovastatin to 40 mg, simvastatin to 20 mg daily
Diltiazem	Lovastatin, Simvastatin	Limit lovastatin to 20 mg, simvastatin to 10 mg daily
Verapamil	Lovastatin, Simvastatin	Limit lovastatin to 20 mg, simvastatin to 10 mg daily
Dronedarone	Lovastatin, Simvastatin	Limit both to 10 mg daily
Gemfibrozil	ALL statins	Avoid combination with all statins (↑ rhabdomyolysis risk). Use fenofibrate instead
Colchicine	Atorvastatin, Fluvastatin, others	Monitor for muscle toxicity
Ticagrelor	Lovastatin, Simvastatin	Limit to 40 mg daily; atorvastatin acceptable without dose limits
Ranolazine	Lovastatin, Simvastatin	Limit to 20 mg daily (use non-CYP3A4 statin if possible)
Bempedoic acid	Pravastatin, Simvastatin	Limit pravastatin to 40 mg, simvastatin to 20 mg daily
Lomitapide	Lovastatin, Simvastatin	Reduce lovastatin by 50%, limit simvastatin by 50% and ≤20 mg daily

Antiretroviral Interactions

Protease inhibitors: Simvastatin and lovastatin are contraindicated. Limit atorvastatin/rosuvastatin doses. Pitavastatin and pravastatin are safe
NNRTIs (efavirenz, etravirine): Adjust statin dose; do not exceed max recommended dose
INSTIs (bictegravir, dolutegravir, raltegravir): Generally no adjustment needed
Elvitegravir/cobicistat: CYP3A4 inhibitor — avoid simvastatin; limit atorvastatin to 20 mg
Pitavastatin was the statin studied in REPRIEVE (35% MACE reduction in HIV) — preferred due to minimal CYP3A4 metabolism

14. Special Populations

Children & Adolescents

Lifestyle management first (COR 1, LOE B-R)
If LDL-C persistently ≥160 with FH and 3–6 months lifestyle fails: initiate statin at age ≥8 (COR 1, LOE B-R)
Genetic testing for FH in children with clinical presentation (COR 2a)
HoFH: aggressive LLT from diagnosis (often in infancy), lipid specialist + pediatric cardiology

Young Adults (18–39 y)

Prioritize lifestyle and weight optimization to reduce cumulative atherogenic lipid exposure (COR 1, LOE B-NR)
If high atherogenic lipid burden + risk enhancers: LLT may be reasonable (clinical judgment)

Older Adults (>75 y)

Consider patient priorities, functional status, multimorbidity, frailty, polypharmacy, life expectancy (COR 1, LOE C-EO)
Estimated life expectancy ≥2.5 y: may be reasonable to initiate moderate-intensity statin (COR 2b, LOE B-NR)
Life expectancy <1 y: reasonable to discontinue LLT for QOL (COR 2b, LOE B-R)
CAC = 0 in absence of diabetes/active smoking: LLT benefits unlikely to outweigh risks
If already on statin for secondary prevention: generally continue unless life expectancy very limited

Pregnancy & Lactation

Stop statins 1–2 months before planned pregnancy or as soon as pregnancy is discovered (COR 1, LOE C-LD)
Bile acid sequestrants are safest during pregnancy (no systemic absorption)
HoFH: lipoprotein apheresis is reasonable during pregnancy (COR 2a)
Severe gestational hypertriglyceridemia (TG ≥500): fibrates (after first trimester) or omega-3 are reasonable to prevent pancreatitis (COR 2a)
Statins may be considered in very high-risk FH/ASCVD patients after individualized benefit-risk discussion (COR 2b)

CKD (Stage 3 or Higher)

CKD ≥ stage 3 without ASCVD, LDL-C 70–189: moderate-intensity statin + ezetimibe recommended (COR 1, LOE B-R)
CKD + clinical ASCVD: high-intensity statin ± ezetimibe ± PCSK9 mAb; LDL-C <55 (COR 1, LOE B-R)
Dialysis: initiation of statin NOT beneficial (4D, AURORA, SHARP subgroup). Continuation of pre-existing statin may be reasonable (COR 2b)
Rosuvastatin concentrations may increase in severe CKD (<30 mL/min) — limit to ≤10 mg. Atorvastatin preferred for renal clearance independence

HIV

Adults 40–75 y on stable ART: statin therapy recommended (COR 1, LOE B-R)
REPRIEVE trial: pitavastatin 4 mg daily → 35% RRR in first MACE (HR 0.65, p=0.002)
Pitavastatin or pravastatin preferred (minimal CYP3A4 metabolism, fewer DDI with ART)

Heart Failure

HFrEF without ASCVD indication: LLT is NOT recommended (COR 3: No Benefit, LOE A) — CORONA and GISSI-HF showed no benefit
HFrEF with ischemic etiology + life expectancy 3–5 y and not on statin: may be reasonable (COR 2b)
If already on statin for ASCVD and develops HF: continue therapy

Chronic Inflammatory Diseases

RA, SLE, psoriatic arthritis, IBD, spondyloarthritis → higher ASCVD risk
Standard risk calculators underestimate risk in CID
LLT can be used safely; monitor lipids as anti-inflammatory therapy (glucocorticoids, hydroxychloroquine, tocilizumab) can modify lipid profiles

Cancer Survivors

≥2-year cancer survivors with life expectancy ≥2 y: treat per standard guidelines (COR 1, LOE B-NR)
Active cancer on statin: continue unless DDI concern or life expectancy <1 y (COR 1, LOE B-NR)
Statins may prevent anthracycline-induced cardiotoxicity (COR 2b, LOE B-R)

15. Medication Safety

Medication	Common Side Effects	Contraindications	Key Safety Points
Statins	Myalgia (normal CK), dose-related	Decompensated cirrhosis; severe neuromuscular diseases (NMDs); pregnancy (relative)	Rhabdomyolysis very rare (~1:100K). Anti-HMGCR necrotizing myopathy very rare. Transaminase elevation >3× ULN in ~3%. Cognitive complaints reversible on discontinuation. Slight ↑ new-onset diabetes (0.06–0.08% HbA1c)
Ezetimibe	Typically well tolerated	Hypersensitivity; moderate-severe hepatic impairment	Monitor hepatic transaminases when adding to statin
PCSK9 mAb	Injection site reactions	Hypersensitivity	Rare angioedema. No latex in alirocumab (but present in some evolocumab devices)
Bempedoic acid	Elevated BUN, creatinine, uric acid	Hypersensitivity	Does NOT cause myalgia (prodrug activated only in liver). Monitor renal function and uric acid
Inclisiran	Injection site reactions	Hypersensitivity	Administered by clinician q6 months. CVOT pending
Fibrates	Myalgia, elevated transaminases	Severe renal/hepatic disease; gallbladder disease; lactation	Gemfibrozil + statin → ↑ rhabdomyolysis. Use fenofibrate. Reversibly elevates creatinine
Omega-3 (IPE)	Eructation, dysgeusia	Hypersensitivity to fish/shellfish	New-onset AF/flutter; increased bleeding events. DHA-containing products can raise LDL-C

16. Neurological Considerations

Stroke Prevention

Ischemic stroke is included as a qualifying ASCVD event for secondary prevention
Post-stroke/TIA patients qualify as "very high risk" if ≥2 major events or 1 event + ≥2 high-risk conditions
High-intensity statin is first-line for secondary stroke prevention; target LDL-C <70 mg/dL (not very high risk) or <55 mg/dL (very high risk)
PCSK9 mAb can be added if not at goal — FOURIER showed 16% reduction in stroke, ODYSSEY showed 27% reduction in stroke with alirocumab

Statin Safety in Neurological Patients

Cognitive effects: Postmarketing reports of memory loss/confusion are generally nonserious, reversible upon discontinuation, and NOT observed in prospective clinical trials. NOT a reason to avoid statins
Hemorrhagic stroke: SPARCL showed modest increased ICH risk with high-dose atorvastatin (HR 1.66). However, overall stroke recurrence was reduced. Guideline does not restrict statin use after ICH
Neuromuscular diseases: Statins are relatively contraindicated in severe NMDs. However, most myopathy patients can tolerate statins at low doses
Anti-HMGCR necrotizing myopathy: Very rare immune-mediated myopathy requiring statin cessation, immunosuppressive therapy. Check anti-HMGCR antibodies if persistent weakness/CK elevation after statin discontinuation
Peripheral neuropathy: Rare case reports; not confirmed in large studies. Not a listed side effect

Drug Interactions Relevant to Neurologists

Antiepileptics: Carbamazepine, phenytoin, phenobarbital (CYP3A4 inducers) may reduce statin efficacy — may need higher statin doses or use non-CYP3A4 statin
Cyclosporine (used in myasthenia gravis, transplant): Increases statin levels — use lowest effective statin dose, avoid simvastatin/lovastatin
Tacrolimus/sirolimus: Can cause dyslipidemia; monitor lipids, adjust statin dose
Colchicine (used in some CNS vasculitis/FMF): Monitor for muscle toxicity when combined with statins